A Randomized, Placebo-controlled, Prospective, Single-blind, Single Center Phase 2 Study of the Efficacy and Safety of SANGUINATE for Reduction of Delayed Graft Function in Recipients of a Donation After Brain Death Kidney Transplant

Trial Profile

A Randomized, Placebo-controlled, Prospective, Single-blind, Single Center Phase 2 Study of the Efficacy and Safety of SANGUINATE for Reduction of Delayed Graft Function in Recipients of a Donation After Brain Death Kidney Transplant

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2016

At a glance

  • Drugs PEG-haemoglobin carbon monoxide (Primary)
  • Indications Delayed graft function
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Prolong Pharmaceuticals
  • Most Recent Events

    • 03 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top